Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Change in gene expression occurs in patients with "pouchitis" after UC surgery

"Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

11 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

CementBloc's GROW campaign and campaign for Giazo awarded top honors at MM&M Awards

The CementBloc's Girls Right of Way campaign for The Coore Foundation and "Mr. Butt" campaign for Giazo have been awarded top honors at the MM&M (Medical Marketing & Media) Awards presentation held in New York City on October 2, 2013.

5 Oct 2013

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

27 Sep 2013

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

...

23 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

UCLA receives multimillion-dollar gift to provide patients with innovative home health program

A multimillion-dollar gift has allowed the UCLA Division of Digestive Diseases to provide patients with an innovative home health program; supported new, minimally invasive treatment procedures; and funded state-of-the-art gastroenterology research.

10 Sep 2013

Human Urine Metabolome Study Envisions New Diagnostic Era

...

6 Sep 2013

More than 3,000 chemicals or "metabolites" can be detected in urine, say researchers

Researchers at the University of Alberta announced today that they have determined the chemical composition of human urine. The study, which took more than seven years and involved a team of nearly 20 researchers, has revealed that more than 3,000 chemicals or "metabolites" can be detected in urine.

6 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.

30 Aug 2013

TAP block procedure poses no significant risks to patients and cuts postoperative use of narcotics

Surgeons at University Hospitals Case Medical Center, Cleveland, are working to reduce serious complications that have been known to occur with colorectal operations.

29 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

A statistical model accounting for dozens of different genes in combination-and the interactions between them-is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD), reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

26 Aug 2013

Understanding genetic factors that affect Crohn's disease risk

A statistical model accounting for dozens of different genes in combination—and the interactions between them—is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

Probiotic does not prevent clinical relapse in patients with Crohn's disease

Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

16 Aug 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Change in gene expression occurs in patients with "pouchitis" after UC surgery

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

CementBloc's GROW campaign and campaign for Giazo awarded top honors at MM&M Awards

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

UCLA receives multimillion-dollar gift to provide patients with innovative home health program

Human Urine Metabolome Study Envisions New Diagnostic Era

More than 3,000 chemicals or "metabolites" can be detected in urine, say researchers

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

TAP block procedure poses no significant risks to patients and cuts postoperative use of narcotics

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

Understanding genetic factors that affect Crohn's disease risk

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Probiotic does not prevent clinical relapse in patients with Crohn's disease

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Forensics and toxicology - Industry Focus eBook eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Forensics and toxicology - Industry Focus eBook eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in